Pegvorhyaluronidase alfa
- Generic Name
- Pegvorhyaluronidase alfa
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1620390-06-8
- Unique Ingredient Identifier
- P01I4980ZS
- Background
Pegvorhyaluronidase alfa is under investigation in clinical trial NCT02241187 (Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection).
- Associated Conditions
- -
- Associated Therapies
- -
MRI Effects of Pegvorhyaluronidase Alfa (PEGPH20) in Pancreatic Ductal Adenocarcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2019-10-22
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT04134468
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Phase 1b Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) Combined With Docetaxel in Subjects With Recurrent Previously Treated Locally Advanced or Metastatic NSCLC
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2015-01-27
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Halozyme Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT02346370
- Locations
- 🇺🇸
California Cancer Associates for Research and Excellence (cCare), Fresno, California, United States
🇺🇸Moores UCSD Cancer Center, Clinical Trials Office, San Diego, California, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath